Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 17289590 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Sapkota G, et al. (2007) Balancing BMP signaling through integrated inputs into the Smad1 linker. Mol Cell 25, 441-54 17289590
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase wild-type
FGF1 increase L/L mutant- lacks 4 MAPK and 1 GSK3 site
BMP2 increase slight increase
EGF increase
UV increase
insulin no change compared to control
hypertonic buffer increase
TGF-beta increase
U0126 no change compared to control
U0126 BMP2 inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase wild-type
FGF1 increase L/L mutant- lacks 4 MAPK and 1 GSK3 site
BMP2 increase slight increase
EGF increase
UV increase
insulin no change compared to control
hypertonic buffer increase
TGF-beta increase
U0126 no change compared to control
U0126 BMP2 inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase wild-type
FGF1 increase L/L mutant- lacks 4 MAPK and 1 GSK3 site
BMP2 increase slight increase
EGF increase
UV increase
insulin no change compared to control
hypertonic buffer increase
TGF-beta increase
U0126 no change compared to control
U0126 BMP2 inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase wild-type
FGF1 increase L/L mutant- lacks 4 MAPK and 1 GSK3 site
BMP2 increase slight increase
EGF increase
UV increase
insulin no change compared to control
hypertonic buffer increase
TGF-beta increase
U0126 no change compared to control
U0126 BMP2 inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase

T183-p - JNK1 (human)
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BMP2 no change compared to control
EGF no change compared to control
UV increase
insulin no change compared to control
hypertonic buffer increase
TGF-beta increase
SB203580 no change compared to control
SB203580 UV inhibit treatment-induced increase
SP600125 UV augment treatment-induced increase

Y185-p - JNK1 (human)
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BMP2 no change compared to control
EGF no change compared to control
UV increase
insulin no change compared to control
hypertonic buffer increase
TGF-beta increase
SB203580 no change compared to control
SB203580 UV inhibit treatment-induced increase
SP600125 UV augment treatment-induced increase

T180-p - P38A (human)
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BMP2 no change compared to control
EGF no change compared to control
UV increase
insulin no change compared to control
hypertonic buffer increase
TGF-beta increase
SB203580 no change compared to control
SB203580 UV inhibit treatment-induced increase
SP600125 UV augment treatment-induced increase

Y182-p - P38A (human)
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BMP2 no change compared to control
EGF no change compared to control
UV increase
insulin no change compared to control
hypertonic buffer increase
TGF-beta increase
SB203580 no change compared to control
SB203580 UV inhibit treatment-induced increase
SP600125 UV augment treatment-induced increase

S187-p - Smad1 (human)
Orthologous residues
Smad1 (human): S187‑p, Smad1 (mouse): S187‑p, Smad1 (rat): S187‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
 Cellular systems studied:  cell lines
 Species studied:  human

S195-p - Smad1 (human)
Orthologous residues
Smad1 (human): S195‑p, Smad1 (mouse): S195‑p, Smad1 (rat): S195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
 Cellular systems studied:  cell lines
 Species studied:  human

T202-p - Smad1 (human)
Orthologous residues
Smad1 (human): T202‑p, Smad1 (mouse): T202‑p, Smad1 (rat): T202‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)

S206-p - Smad1 (human)
Orthologous residues
Smad1 (human): S206‑p, Smad1 (mouse): S206‑p, Smad1 (rat): S206‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase wild-type
FGF1 no effect upon treatment-induced decrease L/L mutant
BMP2 increase
EGF increase
UV increase
insulin no change compared to control
hypertonic buffer increase
TGF-beta increase
EGF no change compared to control nuclear
BMP2, EGF BMP2 augment treatment-induced increase nuclear
EGF increase slight increase, cytosolic
BMP2 EGF augment treatment-induced increase cytosolic
Downstream Regulation
 Effect of modification (function):  intracellular localization, molecular association, regulation, protein degradation, ubiquitination
 Comments:  SMURF1 binds phosphorylated SMAD1 causing cytoplasmic retention or degredation

S214-p - Smad1 (human)
Orthologous residues
Smad1 (human): S214‑p, Smad1 (mouse): S214‑p, Smad1 (rat): S214‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
 Cellular systems studied:  cell lines
 Species studied:  human


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.